Director, Alternative Site of Care Strategy Lead
Intellia Therapeutics, Inc.
Summary
The Director, Alternative Site of Care Strategy Lead will play a key leadership role in advancing Intellia's site-of-care capabilities. This role will help shape and execute approaches for engaging alternative sites of care and other infusion providers, with a focus on creating a high-quality, consistent experience for patients and providers. This is a highly cross-functional role requiring strong strategic thinking, operational leadership, and stakeholder management.
Job description
Duties/Responsibilities
Strategy & Channel Ownership
- Serve as the single owner and strategic lead for the ASOC channel, defining the criteria, sequencing, and roadmap for which independent infusion providers to prioritize and onboard.
- Develop the business case, resourcing plan, and success metrics for ASOC integration, in partnership with the VP of Sales and Strategic Accounts leadership.
- Track and report progress against the operationalization plan, including timing, budget, and risk to the target go-live window.
Provider Engagement & Contracting
- Lead direct outreach, relationship-building, and negotiation with independent infusion providers to bring them into the Lonvo-z ATC network as ASOCs.
- Partner with Legal and Market Access to negotiate and finalize contracting terms with selected ASOC partners.
- Serve as the primary relationship owner for onboarded ASOC accounts post-contracting, ensuring a smooth transition into active network status.
Cross-Functional Leadership & Coordination
Act as the connective tissue across internal functions to ensure each workstream is executed on time and in an integrated fashion, including:
- Field: Align with Sales Account Leads (SAL), Patient Access Leads (PAL), and Nurse Case Managers (NCM) to build the capacity and playbooks needed to support ASOCs alongside existing ATCs.
- Marketing: Direct development of new ASOC-specific assets and adaptation of existing ATC materials for applicability to the ASOC channel.
- Patient Services: Partner on Travel & Lodging modeling, Hub workflow integration, and development of forms/processes for the new ASOC patient pathway.
- Medical: Support Medical Affairs on Lonvo-z clinical data discussions, protocol development, and HAE education/training relevant to ASOC providers (e.g., attack vs. anaphylaxis recognition, treatment response).
- Market Access: Partner on GTN, ASP modeling, and FMV assessment specific to the ASOC channel.
- Commercial Operations: Ensure ASOC accounts are built out in CRM system and properly incorporated into forecasting as a distinct source of business.
- IT: Coordinate execution of data integrations (e.g., status reporting) into the CDE to support ASOC visibility and reporting.
Governance & Reporting
- Provide regular updates to the VP of Sales and relevant governance bodies on progress, budget, and risks.
- Support preparation of the full financial impact assessment and business case for formal approval.
Requirements
- Bachelor's degree required; advanced degree (MBA, MHA, or related) preferred.
- 10+ years of experience in biotech/pharma commercial roles, with direct experience in specialty pharmacy, infusion services, site-of-care strategy, trade/distribution, or strategic account management.
- Demonstrated experience building or scaling a new channel, program, or network from the ground up, ideally involving external provider contracting/negotiation.
- Experience working directly with alternative sites of care or independent infusion providers required.
- Proven ability to lead complex, matrixed, cross-functional initiatives without direct authority over contributing teams.
- Experience in rare disease and/or launch-stage commercial environments preferred; familiarity with hereditary angioedema (HAE) or gene-editing therapies a plus.
- Strong contracting/negotiation acumen; comfort partnering closely with Legal and Market Access on deal terms.
- Excellent executive communication skills; able to synthesize complex, multi-workstream status into clear updates for senior leadership.
- Willingness to travel extensively (estimated 40–60%) to engage independent infusion providers nationally.
Benefits
- Performance-based annual cash bonus
- New hire equity grant
- Annual equity awards
- Health insurance
Company overview
Intellia Therapeutics, Inc. is a leading clinical-stage biotechnology company focused on revolutionizing medicine through CRISPR-based gene editing therapies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company leverages Nobel Prize-winning CRISPR/Cas9 technology to develop potentially curative treatments for severe genetic diseases. Intellia operates with a dual approach: in vivo programs that use intravenously administered CRISPR to edit disease-causing genes directly within the body, and ex vivo programs that engineer human cells outside the body to treat cancer and autoimmune diseases. The company's pipeline includes advanced clinical programs for hereditary angioedema (NTLA-2002) and transthyretin amyloidosis (NTLA-2001), both in late-stage clinical trials. Intellia has established strategic collaborations with major pharmaceutical companies including Regeneron and Novartis, and maintains a strong intellectual property portfolio with over 400 patent documents. As a publicly traded company (NASDAQ: NTLA) with approximately 500-1,000 employees, Intellia represents a pioneering force in the gene editing space, working to transform the treatment paradigm for patients with serious genetic disorders through one-time, potentially curative therapies.